首站-论文投稿智能助手
典型文献
ADT-OH inhibits malignant melanoma metastasis in mice via suppressing CSE/CBS and FAK/Paxillin signaling pathway
文献摘要:
Hydrogen sulfide(H2S)is widely recognized as the third endogenous gas signaling molecule and may play a key role in cancer biological processes.ADT-OH(5-(4-hydroxyphenyl)-3H-1,2-dithiocyclopentene-3-thione)is one of the most widely used organic donors for the slow release of H2S and considered to be a potential anticancer compound.In this study,we investigated the antimetastatic effects of ADT-OH in highly metastatic melanoma cells.A tail-vein-metastasis model was established by injecting B16F10 and A375 cells into the tail veins of mice,whereas a mouse footpad-injection model was established by injecting B16F10 cells into mouse footpads.We showed that administration of ADT-OH significantly inhibited the migration and invasion of melanoma cells in the three different animal models.We further showed that ADT-OH dose-dependently inhibited the migration and invasion of B16F10,B16F1 and A375 melanoma cells as evaluated by wound healing and Transwell assays in vitro.LC-MS/MS and bioinformatics analyses revealed that ADT-OH treatment inhibited the EMT process in B16F10 and A375 cells by reducing the expression of FAK and the downstream response protein Paxillin.Overexpression of FAK reversed the inhibitory effects of ADT-OH on melanoma cell migration.Moreover,after ADT-OH treatment,melanoma cells showed abnormal expression of the H2S-producing enzymes CSE/CBS and the AKT signaling pathways.In addition,ADT-OH significantly suppressed the proliferation of melanoma cells.Collectively,these results demonstrate that ADT-OH inhibits the EMT process in melanoma cells by suppressing the CSE/CBS and FAK signaling pathways,thereby exerting its antimetastatic activity.ADT-OH may be used as an antimetastatic agent in the future.
文献关键词:
作者姓名:
Fang-fang Cai;Huang-ru Xu;Shi-hui Yu;Ping Li;Yan-yan Lu;Jia Chen;Zhi-qian Bi;Hui-song Sun;Jian Cheng;Hong-qin Zhuang;Zi-chun Hua
作者机构:
The State Key Laboratory of Pharmaceutical Biotechnology,College of Life Sciences,Nanjing University,Nanjing 210008,China;Schoolof Biopharmacy,China Pharmaceutical University,Nanjing 211198,China;Institute of Neuroscience,Soochow University,Suzhou 215031,China;Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc.,Changzhou 213164,China
引用格式:
[1]Fang-fang Cai;Huang-ru Xu;Shi-hui Yu;Ping Li;Yan-yan Lu;Jia Chen;Zhi-qian Bi;Hui-song Sun;Jian Cheng;Hong-qin Zhuang;Zi-chun Hua-.ADT-OH inhibits malignant melanoma metastasis in mice via suppressing CSE/CBS and FAK/Paxillin signaling pathway)[J].中国药理学报(英文版),2022(07):1829-1842
A类:
dithiocyclopentene,antimetastatic,B16F1
B类:
ADT,inhibits,malignant,melanoma,metastasis,mice,via,suppressing,CSE,CBS,FAK,Paxillin,signaling,Hydrogen,sulfide,H2S,widely,recognized,third,endogenous,gas,molecule,may,play,key,role,biological,processes,hydroxyphenyl,3H,thione,most,used,organic,donors,slow,release,considered,be,potential,anticancer,compound,In,this,study,investigated,effects,highly,cells,tail,was,established,injecting,B16F10,A375,into,veins,whereas,mouse,injection,footpads,We,showed,that,administration,significantly,inhibited,migration,invasion,three,different,animal,models,further,dose,dependently,evaluated,wound,healing,Transwell,assays,vitro,LC,bioinformatics,analyses,revealed,treatment,EMT,reducing,downstream,response,protein,Overexpression,reversed,inhibitory,Moreover,after,abnormal,producing,enzymes,AKT,pathways,addition,suppressed,proliferation,Collectively,these,results,demonstrate,thereby,exerting,activity,agent,future
AB值:
0.454274
相似文献
Romidepsin (FK228) improves the survival of allogeneic skin grafts through downregulating the production of donor-specific antibody via suppressing the IRE1 α-XBP1 pathway
Yuliang GUO;Siyu SONG;Xiaoxiao DU;Li TIAN;Man ZHANG;Hongmin ZHOU;Zhonghua Klaus CHEN;Sheng CHANG-Institute of Organ Transplantation,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Key Laboratory of Organ Transplantation,Ministry of Education,NHC Key Laboratory of Organ Transplantation,Key Laboratory of Organ Transplantation,Chinese Academy of Medical Sciences,Wuhan 430030,China;Henan Key Laboratory of Digestive Organ Transplantation,Open and Key Laboratory of Hepatobiliary&Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities,Zhengzhou Key Laboratory of Hepatobiliary&Pancreatic Diseases and Organ Transplantation,Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Cardiothoracic and Vascular Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
N6?methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance
Xian Lin;Feng Wang;Jian Chen;Jing Liu;Yi?Bin Lin;Li Li;Chuan?Ben Chen;Qin Xu-Departments of Gynecology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Department of Radiation Oncology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Shenzhen Key Laboratory of Immunity and Inflammatory Diseases,Peking University Shenzhen Hospital,Shenzhen Peking University?the Hong Kong University of Science and Technology Medical Center,Shenzhen 518036,Guangdong,China;Outpatient Department,Fujian Hospital of People's Armed Police,Fujian Medical University,Fuzhou 350014,China
SNORA23 inhibits HCC tumorigenesis by impairing the 2?-O-ribose methylation level of 28S rRNA
Zhiyong Liu;Yanan Pang;Yin Jia;Qin Qin;Rui Wang;Wei Li;Jie Jing;Haidong Liu;Shanrong Liu-Department of Laboratory Diagnostics,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Department of Gastroenterology and Hepatology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Gastroenterology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Institute of Pancreatic Diseases,Shanghai 200433,China;Department of Chemistry and State Key Laboratory of Molecular Engineering of Polymers,Fudan University,Shanghai 200433 China;Department of General Surgery,Changzheng Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。